EYA4 Polyclonal Antibody, Cy5.5 Conjugated
Applications
Predicted Reactivity
| Overview | |
| Catalog # | bs-13126R-Cy5.5-100uL |
| Product Name | EYA4 Polyclonal Antibody, Cy5.5 Conjugated |
| Applications |
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Predicted Reactivity | Human, Mouse, Rat, Dog, Cow, Sheep, Pig, Horse |
| Specifications | |
| Conjugation | Cy5.5 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human EYA4 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 2070 |
| Subcellular location | Cytoplasm, Nucleus |
| Synonyms | CMD1J; Deafness, autosomal dominant 10; DFNA 10; DFNA10; dJ78N10.1 eyes absent Drosophila homolog 4; dJ78N10.1 eyes absent; EYA 4; eya4; EYA4_HUMAN; Eyes absent 4; Eyes absent homolog 4 Drosophila; Eyes absent homolog 4; HGNC:3522; OTTHUMP00000040267. |
| Background | A gene of chromosome 6q23 encodes the 640 amino acid protein, EYA4 (eyes absent) (1). EYA is one of four members of the eyes absent family (1). A 271 amino acid domain at the carboxyl terminal is highly conserved amongst the members of the eyes absent family (1). EYA4 is expressed in the craniofacial mesenchyme, the dermamyotome, and the limb (1). The conserved region in other EYA proteins interacts with SIX, DACH, and G-proteins, which regulate transcription in early embryonic development (1,2,3,4). SIX translocates EYA1-3 to the nucleus, and G-proteins can stop this interaction (3,4). Premature stop codon mutations in EYA4 cause postlingual, progressive autosomal dominant hearing loss in humans (2). This shows that EYA4 is also vital to the mature organ of Corti (2). EYA4 may cause oculo-dento-digital syndrome, based on its expression pattern and map postion (1). |
| Application Dilution | |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |
Frequently asked questions
Which applications is EYA4 Polyclonal Antibody, Cy5.5 Conjugated (BS-13126R-CY5-5) validated for, and at what dilution?
BS-13126R-CY5-5 is validated for IF(IHC-P) (1:50-200); IF(IHC-F) (1:50-200); IF(ICC) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
How should BS-13126R-CY5-5 be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise EYA4 Polyclonal Antibody, Cy5.5 Conjugated (BS-13126R-CY5-5)?
KLH conjugated synthetic peptide derived from human EYA4
What are the excitation and emission wavelengths of the Cy5.5 conjugate (BS-13126R-CY5-5)?
Cy5.5 on BS-13126R-CY5-5: excitation / emission 675nm/694nm.